PTC Therapeutics develops and commercializes medicines for children and adults with rare disorders, with a life-science business focused on clinically differentiated therapies in areas including neurology and metabolism. Company news commonly covers product revenue, commercial launch activity, financial guidance, investor presentations, and updates from its rare-disease development portfolio.
Recurring developments include Sephience™ (sepiapterin) launch and revenue updates, clinical and regulatory disclosures involving votoplam, vatiquinone and Translarna™ (ataluren), and partnership-related program responsibilities. PTC also reports governance changes and Nasdaq inducement equity grants tied to employee compensation.
PTC Therapeutics, Inc. (NASDAQ: PTCT) has received FDA authorization to initiate a Phase 2/3 clinical trial for PTC299, a dihydroorotate dehydrogenase (DHODH) inhibitor, aimed at treating COVID-19. The trial, starting imminently in the U.S. and expanding globally, will evaluate the drug's efficacy in reducing SARS-CoV-2 replication and managing inflammation associated with COVID-19. The study will involve around 340 patients, measuring clinical efficacy against a placebo through respiratory improvement. PTC299 is also under investigation for oncology applications, having shown promising results in prior trials.